This week PR Newswire carried an announcement by the biotechnology company Immunic Inc. of preclinical data confirming that Vidofludimus Calcium (IMU 838) may be a Nurr 1-Activator reinforcement. Immunic is…
Rare Community Profiles Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their families,…
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
Over the past few decades, research has shown a potential connection between metabolic disorders and multiple sclerosis (MS). While this connection has been made, anti-hyperglycemic medications (often used to…
There is no cure for multiple sclerosis (MS). However, treatment advances have helped people to live longer, happier lives. Current therapeutic options include corticosteroids, plasmapheresis, and disease-modifying drugs. Recently,…
Before you read on, make sure to check out Part 1 of Jennifer's story. In Part 1, we discuss what multiple sclerosis is, its symptoms, treatment options, and Jennifer's journey from diagnosis…
If there is one lesson that Jennifer embodies in full, it’s this: always live life to your fullest. That’s what Jennifer aims to do every day. As an education consultant,…
Currently, there are no cures for multiple sclerosis (MS). Treatment options typically focus on slowing disease progression, reducing relapses, and managing symptoms. Patients with relapsing-remitting multiple sclerosis often experience episodes,…
According to a story from PR Newswire, Immunic, Inc., a biopharmaceutical company prioritizing the development of oral immunology medicines for the treatment of chronic inflammatory and autoimmune disorders, has reported…
Currently, there is no known cause for multiple sclerosis (MS). While many doctors consider MS to be an autoimmune disease, nobody knows what prompts this immune response. A combination…
Dr. Sergio Baranzini of UC San Francisco recently led an international consortium of researchers in a new study of multiple sclerosis (MS). In a press release on Multiple Sclerosis…
Near the start of August 2022, biotechnology company Inmagene Biopharmaceuticals ("Inmagene") and biopharmaceutical company HUTCHMED shared via news release that the first participant had been dosed in a Phase…
Don't forget to check out Part 1, where we discussed what multiple sclerosis (MS) is, went over Mo's diagnostic journey, and began talking about the importance of awareness. Treating Multiple Sclerosis…
For as long as she can remember, 30-year-old Ankona “Mo” Das has loved traveling. Traveling has provided a way to break out of her shell, to experience new landscapes, and…
Currently, there is no way to determine when a relapse will occur in relapsing and remitting multiple sclerosis (MS), one of the two main forms of MS. However, this may…
What causes “attacks,” or periods of intense symptoms, in those with multiple sclerosis (MS)? In the past, research has suggested that viral infections or even certain bacteria could play a…
In the past, many researchers have hypothesized a link between multiple sclerosis (MS) and different viruses or viral infections. While these hypotheses are varied in nature, there has rarely been…
Past research has shown that rogue Th17 cells could help spur the manifestation of autoimmune conditions like multiple sclerosis (MS). But why do these cells go wrong and how could…
Biogen Inc. recently announced data that included extended results from its earlier Phase 3b NOVA study on the administration of natalizumab and the evaluation of the drugs Tysabri® and Vumerity. …
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
A recent article from Healthline highlighted the similarities and differences between two neurological diseases, myasthenia gravis (MG) and multiple sclerosis (MS). Myasthenia Gravis Deriving from the Greek and Latin words…
In 2019, the United States approved Vumerity (diroximel fumarate) to treat adult patients with relapsing-remitting (R/R) multiple sclerosis (MS). Now, two years later, the European Union has approved this…
Atara Therapeutics has released data from its Phase 1 open-label extension (OLE) trial of ATA188, a treatment for progressive multiple sclerosis (MS). This allogeneic T-cell immunotherapy targets B cells and…
The 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) was held last week from the 13th to the 15th. This event is the largest…
Kristin woke up the morning of her 19th birthday with a startling realization: she was unable to speak. It was hard to describe the feeling, but when she tried to…
© Copyright Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
